Table 1.
Patient characteristics
|
Treatment group |
||
| CAPIRI | CAPIRI-Bev | |
| N (%) | 17 (37%) | 29 (63%) |
| Age (median), years (range) | 66 (55-81) | 60 (37-80) |
| Gender, M/F | 9/8 | 22/7 |
| Site of primary tumor, n (%) | ||
| Rectum | 7 (41.2) | 15 (51.7) |
| Colon | 10 (58.8) | 14 (48.2) |
| Site of metastases, n (%)1 | ||
| Hepatic | 12 (71) | 24 (83) |
| Pulmonary | 6 (35) | 11 (38) |
| Lymphatic and nodal | 4 (24) | 17 (59) |
| Skeletal | 1 (6) | 4 (14) |
| Peritoneal | 1 (6) | 5 (17) |
| Other sites | 6 (35) | 5 (17) |
| Performance status (Karnofsky) | ||
| 100% | 4 (23.5) | 17 (58.6) |
| 90% | 1 (5.9) | 5 (17.2) |
| 85% | 1 (5.9) | 0 (0) |
| 80% | 2 (11.8) | 3 (10.3) |
| 70% | 4 (23.5) | 0 (0) |
| Adjuvant chemotherapy received | 8 (47%) | 8 (27.6%) |
1
Patients could have more than one metastatic site.